What C4X does
To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.
It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.
This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.
Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.
It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).
It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.
Below is the company’s drug pipeline
The company is well-funded with just £9mln in the bank at the end of January having successfully concluded a £10.1mln City fundraiser last October. Its net assets are valued at £12.8mln.
On 24 October, C4X unveiled plans to raise around £6.5mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.
In a recent business update, C4X said it was “very confident” of delivering deals in the near future. It said it is in licensing discussions with potential partners for two of its early-stage drugs, while collaborations with two life sciences groups are making progress.
Chief executive Clive Dix said its NRF-2 activator had the potential to become an alternative treatment for people poorly served by the current sickle cell medication. This is supported by recent industry data on the condition.
In the update, C4X also noted there had been “strong interest from potential partners” for its oral IL-17 inhibitor for inflammation.
Its partnership with LifeArc, announced just under a year ago, is also proving a success, while another tie-up, this time with AIM-listed Horizon Developments (LON:HZD), inked last December, has made “rapid progress”.
"We ended up generating data that showed in sickle cell disease it looks like it will be a phenomenal drug, and that it may be disease-modifying and therefore changing the lives of people with a disease that is quite a difficult disease to treat," said CEO Dix.
“We now know that there is an even broader group of people out there interested in this than we thought because of the data we have generated, so we have taken a slight step back, we want to make sure we capture all of those companies in those discussions."